KDA Group settles **$695,051 in debt** with ten creditors by issuing **11.6 million Class A shares** at **$0.06 per share** and an equal number of warrants exercisable at **$0.10** over 24 months. The agreement awaits approval from the TSX Venture Exchange.
The **CHU de Québec – Université Laval** demonstrates how digital follow-up improves adherence to oral breast cancer therapies. KDA Group acknowledges the pilot’s success and plans to extend the partnership to additional projects supporting care teams and patients. The collaboration focuses on enhancing treatment management through digital tools.
KDA Group Inc. appoints Louise Potvin as a new director, replacing Dr. Jacques Turgeon, who resigned. Potvin brings over 40 years of experience in Quebec’s health and social services sector, including leadership roles at major institutions. Her background combines clinical expertise, executive leadership, and governance experience, strengthening the board’s strategic capabilities.
CHU de Québec – Université Laval validates Medherize’s breast oncology platform with 243 patients using targeted oral therapies. The evaluation shows **97% adoption**, **93% treatment adherence**, and **17% treatment interruptions**—half the typical rate. Pharmacist workload drops by **52%**, reducing full-time equivalent needs.
